S. Frings

1.4k total citations
9 papers, 317 citations indexed

About

S. Frings is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Frings has authored 9 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 2 papers in Surgery and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Frings's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Colorectal Cancer Surgical Treatments (2 papers). S. Frings is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and Colorectal Cancer Surgical Treatments (2 papers). S. Frings collaborates with scholars based in Germany, United States and Switzerland. S. Frings's co-authors include Thomas S. Reese, Jürgen Dunst, H Zühlke, Thomas R. Sutter, Axel Hinke, W. Achterrath, S. Seeber, A. Harstrick, U. Vanhoefer and Youcef M. Rustum and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

S. Frings

9 papers receiving 308 citations

Peers

Countries citing papers authored by S. Frings

Since Specialization

Citations

This map shows the geographic impact of S. Frings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Frings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Frings more than expected).

Fields of papers citing papers by S. Frings

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Frings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Frings. The network helps show where S. Frings may publish in the future.

Co-authorship network of co-authors of S. Frings

This figure shows the co-authorship network connecting the top 25 collaborators of S. Frings. A scholar is included among the top collaborators of S. Frings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Frings. S. Frings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry 2013 ·Annals of Oncology ·Rupert Bartsch, S. Frings, (unknown), Ahmad Awada, Anna S. Berghoff, Pierfranco Conté, (unknown), Harald Enzmann, Michael Gnant, Max Hasmann, Hans R. Hendriks, Antonio Llombart‐Cussac, Cristian Massacesi, Gϋnter von Minckwitz, (unknown), Maurizio Scaltriti, Y Yarden, H. Zwierzina, Christoph Zielinski	7
2	New Molecular Targeted Therapeutic Drugs Clinical Results of Bevacizumab in Non-Small Cell Lung Cancer (NSCLC) 2006 ·Haigan ·S. Frings	1
3	Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study† 2003 ·Annals of Oncology ·Mitra Tewes, N. Schleucher, W. Achterrath, Hans‐Joachim Wilke, S. Frings, S. Seeber, A. Harstrick, Youcef M. Rustum, U. Vanhoefer	46
4	Phase I Trial Evaluating the Concurrent Combination of Radiotherapy and Capecitabine in Rectal Cancer 2002 ·Journal of Clinical Oncology ·Jürgen Dunst, Thomas S. Reese, Thomas R. Sutter, H Zühlke, Axel Hinke, (unknown), S. Frings	182
5	CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC): preliminary results of a phase I/II study 2001 ·European Journal of Cancer ·DJ Kerr, W W ten Bokkel Huinink, (unknown), (unknown), S. Frings, J.W.R. Nortier	13
6	Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxane-containing chemotherapy? Mature results of a large multicenter phase II trial 2001 ·European Journal of Cancer ·Peter Reichardt, Gϋnter von Minckwitz, (unknown), P. Thuss-Patience, W. Jonat, H Kölbl, (unknown), W Kühn, (unknown), S. Frings	30
7	Extended phase I study of capecitabine and weekly irinotecan as first-line chemotherapy in metastatic colorectal cancer 2001 ·European Journal of Cancer ·N. Schleucher, Mitra Tewes, W. Achterrath, Shu Cao, S. Frings, (unknown), A. Harstrick, Youcef M. Rustum, S. Seeber, U. Vanhoefer	9
8	Capecitabine combined with simultaneous radiotherapy in rectal cancer: A phase-I-study 2000 ·International Journal of Radiation OncologyBiologyPhysics ·Thomas S. Reese, Judith Tanner, S. Frings, Jürgen Dunst	17
9	Capecitabine – a Novel Oral Tumor-Activated Fluoropyrimidine 1998 ·Oncology Research and Treatment ·S. Frings	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact